Glucocerebrosidase Mutations and Parkinson's Disease Dynamics

Glucocerebrosidase (GCase), the lysosomal enzyme encoded by the GBA1 gene, plays a central role in maintaining lipid homeostasis and protein clearance within neurons. Mutations in GBA1 give rise to reduced GCase activity, leading to lysosomal dysfunction, impaired autophagy and accumulation of α-synuclein aggregates—hallmarks of Parkinson’s disease (PD) pathology. Recent work has revealed that GCase also localises to mitochondria, where it supports complex I integrity and energy metabolism. The interplay between impaired lysosomal clearance and mitochondrial stress creates a self-reinforcing cycle of neurodegeneration. Beyond neurons, glial cells such as oligodendrocytes contribute to disease progression through disrupted myelination and lipid dyshomeostasis. Clinically, GBA1-associated PD often presents with earlier onset, more rapid motor decline and heightened cognitive impairment. Global efforts have focused on defining genotype–phenotype correlations, identifying biomarkers of GCase activity and α-synuclein burden, and developing targeted therapies—including small-molecule chaperones and gene-delivery platforms—to restore enzyme function and halt disease progression.

Research from Nature Portfolio

A comprehensive study using proteomic and single-cell genomic techniques in cell lines, induced pluripotent stem cell (iPSC)-derived neurons and midbrain organoids has demonstrated that GCase contains internal mitochondrial targeting signals enabling its import into mitochondria. Once inside, GCase preserves the stability and function of mitochondrial complex I, interacts with quality-control chaperones and proteases, and maintains cellular energy metabolism. Disease-associated GBA1 mutations disrupt these processes, compromise complex I integrity and exacerbate mitochondrial dysfunction, suggesting that defective energy metabolism is a key driver of GBA1-linked neurodegeneration.

Glucocerebrosidase Mutations and Parkinson's Disease Dynamics publication trend

The graph below shows the total number of articles in glucocerebrosidase mutations and parkinson's disease dynamics across all publications each year (not limited to Nature Index journals).

Technical terms

Glucocerebrosidase (GCase): A lysosomal hydrolase that degrades glucosylceramide; its deficiency impairs autophagy and promotes α-synuclein aggregation.

GBA1: The gene encoding GCase; mutations confer the most common genetic risk for Parkinson’s disease.

α-Synuclein: A presynaptic neuronal protein that aggregates into Lewy bodies and drives neurodegeneration in PD.

Mitochondrial complex I: The first enzyme of the oxidative phosphorylation chain; its integrity is crucial for cellular energy production.

Oligodendrocyte: A glial cell responsible for myelin production in the central nervous system; dysfunction contributes to neurodegenerative pathology.

References

1. Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism. Nature Communications (2023).
2. GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice. Molecular Neurodegeneration (2024).
3. Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson’s disease. Translational Neurodegeneration (2024).